Zofran dose per kg
Usual Adult Dose for Nausea/Vomiting
If ondansetron and procainamide must be coadministered, ECG monitoring is recommended. Use ondansetron with caution in patients with cardiac disease or other conditions that may increase the risk of QT prolongation including cardiac arrhythmias, heart failure, bradycardia, myocardial infarction, hypertension, coronary artery disease, hypomagnesemia, hypokalemia, hypocalcemia, or in patients receiving medications known to cause electrolyte imbalances.
Non-Medicare Plans Medicare Plans. Severe Concomitant administration of posaconazole and drugs that both prolong the QT interval and are CYP3A4 substrates is contraindicated according to the FDA-approved product labeling. However, these changes in ondansetron exposure are not thought to be clinically relevant; no dosage adjustment for ondansetron is recommended when CYP inducers are used concurrently.
Although routine use of antiemetics is not recommended for acute gastroenteritis in guidelines available from the American Academy of Pediatrics and Centers for Disease Control, some studies have found that single and multiple oral doses of ondansetron are safe and effective for reducing vomiting and increasing patients' ability to tolerate oral rehydration. To see the full article, log in or purchase access.
This restriction typically requires that certain criteria be met prior to approval for the prescription. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
Select a medication above to begin.
Ondansetron has been associated with QT prolongation and post-marketing reports of torsade de pointes TdP. Most commonly, these are "preferred" on formulary brand drugs. Oculogyric crisis, appearing alone, as well as with other dystonic reactions; transient dizziness during or shortly after intravenous infusion Skin and subcutaneous tissue: According to the manufacturer of conivaptan, concomitant use of conivaptan, a strong CYP3A4 inhibitor, and CYP3A substrates, such as ondansetron, should be avoided.
Hypersensitivity reactions including anaphylaxis and bronchospasm may occur: Acute cardiotoxicity can occur during the administration of idarubicin; although, the incidence is rare. An interruption of therapy, dose reduction, or discontinuation of therapy may be necessary for crizotinib patients if QT prolongation occurs.
In addition, concentrations of ondansetron may be increased with concomitant use of quinine. If ondansetron and posaconazole are administered together, extreme caution and careful monitoring is advised, especially if higher doses are used or if other drugs that may affect CYP1A2 or CYP2D6 are also given. Major Due to the potential for QT prolongation and torsade de pointes TdPcaution is advised when administering ondansetron with flecainide.
Major If ondansetron and tizanidine must be coadministered, ECG monitoring is recommended. If ondansetron dose adjustments are made, re-adjust the dose upon completion of telaprevir treatment. Contact the applicable plan provider for the most current information.
Cabozantinib is a P-glycoprotein P-gp inhibitor and ondansetron is a substrate of P-gp; the clinical relevance of this finding is unknown. Venlafaxine administration is associated with a possible risk of QT prolongation; TdP has reported with post-marketing use.
Dasabuvir; Ombitasvir; Paritaprevir; Ritonavir: Less than 40 kg: What would you like to print? Quantity Limits Drugs that have quantity limits associated with each prescription.
Although this interaction has not been studied, predictions about the interaction can be made based on the metabolic pathway of ondansetron.